Monthly Archives: September 2012

In re Peter Droge, et al.

Docket No. 2011-1600 NEWMAN, MOORE, O’MALLEY September 21, 2012 Brief summary: Use of modified recombination proteins in eukaryotic cells found obvious in view of prior art showing use in prokaryotic cells in the absence of prokaryotic accessory factors (“[o]bviousness does … Continue reading

Posted in Obviousness | Leave a comment

K-Tec, Inc. v. Vita-Mix Corporation

Docket No. 2011-1244, -1484, -1512 NEWMAN, LOURIE, PROST September 6, 2012 Brief Summary: Expert declaration alone regarding simple technology may not be enough to raise genuine issue of material fact and analogous prior art is that which “logically would have … Continue reading

Posted in Obviousness | Leave a comment

Santarus, Inc. et al. vs. Par Pharmaceutical, Inc.

Docket No. 2010-1360, -1380 RADER, NEWMAN (C/D), MOORE September 4, 2012 Brief summary: Negative claim limitations may be supported where specification describes a reason to exclude the relevant limitation; parent application of CIP may be prior art; teaching away must … Continue reading

Posted in Obviousness, Priority, Written description | Leave a comment